Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.
A new study funded by Sandoz indicated that expanding access to biosimilar pegfilgrastim (Ziextenzo) to patients at intermediate risk of developing febrile neutropenia (FN) and converting patients at high risk who are already taking the reference product (Neulasta) could save millions of dollars in health care costs.
Reference pegfilgrastim tends to be prescribed only for patients with cancer who are at a high risk of FN, rather than for those who are at intermediate and low risk, due to its high cost.
A poster on the study was presented during the Academy of Managed Care Pharmacy’s AMCP eLearning Days virtual meeting in April.
“Expanding biosimilar pegfilgrastim prophylaxis to patients at intermediate risk of FN would not only reduce total costs but also reduce healthcare resource utilization, including hospitalization and emergency department visits,” said Weijia Wang, MSc, an associate director at Sandoz and the study’s lead author.
The investigators created a 5-year projection of savings from converting patients from reference to biosimilar pegfilgrastim and applied it to a hypothetical 1-million member health plan with a mixture of commercial payer and Medicare plan participants. Converting patients at high risk of FN to the biosimilar would have resulted in savings of $5.3 million in 2020, rising to $32.8 million by 2024, researchers said.
To read more of this story, visit The Center for Biosimilars.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More